十六烷基三甲基氟化铵 | 14002-56-3

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 十六烷基三甲基氟化铵
• 英文名称: cetyltrimethylammonium fluoride
• 英文别名: 1-Hexadecanaminium, N,N,N-trimethyl-, fluoride；hexadecyl(trimethyl)azanium;fluoride
• CAS: 14002-56-3
• 化学式: C₁₉H₄₂N*F
• 分子量: 303.548
• InChiKey: ZSNUOIONTCOONQ-UHFFFAOYSA-M

物化性质

• 熔点：
  246-249 °C (decomp)

计算性质

• 辛醇/水分配系数(LogP)：
  3.18
• 重原子数：
  21
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2923900090

反应信息

• 作为产物：
  描述：

  十六烷基三甲基氯化铵 在 potassium fluoride 作用下， 以 甲醇 为溶剂， 反应 0.5h， 生成 十六烷基三甲基氟化铵
  参考文献：
  名称：

  Synthesis of quaternary ammonium fluoride salts by a solid-liquid halogen exchange process in protic solvents

  摘要：

  DOI：

  10.1021/jo00281a024
• 作为试剂：
  描述：

  (4-硝基苯基)二苯基磷酸酯 在 十六烷基三甲基氟化铵 氢氟酸 作用下， 以 水 为溶剂， 生成 diphenyl phosphorofluoridate
  参考文献：
  名称：

  对硝基苯基二苯基磷酸酯在十六烷基三甲基氟化铵中的反应

  摘要：

  DOI：

  10.1021/j100457a026

文献信息

• Organic metal compound and process for preparing optically-active alcohols using the same
  申请人：Miki Takashi

  公开号：US20090062573A1

  公开（公告）日：2009-03-05

  The present invention provides an asymmetric reduction catalyst effective in preparing optically-active alcohol compounds having various functional groups, and a process for preparing optically-active alcohol compounds using said asymmetric reduction catalyst. The organic metal compound of the present invention is represented by the following general formula (1): wherein R 1 and R 2 may be mutually identical or different, and are an alkyl group, a phenyl group, a naphthyl group, a cycloalkyl group, or an alicyclic ring formed by binding R 1 and R 2 , which may have a substituent; R 3 is a hydrogen atom or an alkyl group; Cp is a cyclopentadienyl group, which may have a substituent, bound to M 1 via a π bond; X 1 is a halogen atom or a hydrido group; M 1 is rhodium or iridium; and * denotes asymmetric carbon.

  本发明提供了一种在制备具有各种官能团的光学活性醇化合物中有效的非对称还原催化剂，以及使用所述非对称还原催化剂制备光学活性醇化合物的方法。 本发明的有机金属化合物由以下通式(1)表示： 其中R1和R2可以相互相同或不同，并且是烷基、苯基、萘基、环烷基或由R1和R2结合形成的脂肪环环，其中可能含有取代基；R3是氢原子或烷基；Cp是环戊二烯基，可能含有取代基，通过π键与M1结合；X1是卤素原子或氢化物基团；M1是铑或铱；*表示不对称碳。
• ASYMMETRIC CATALYST AND PROCESS FOR PREPARING OPTICALLY ACTIVE ALCOHOLS USING THE SAME
  申请人：Watanabe Masahito

  公开号：US20100261924A1

  公开（公告）日：2010-10-14

  The present invention provides an organic metal compound, a ligand, an asymmetric catalyst, and a process for preparing optically-active alcohols using the asymmetric catalyst. The organic metal compound of the present invention is expressed by the following general formula (1): wherein in general formula (1), R 1 and R 2 are a mutually identical or mutually different, unsubstituted or substituted alkyl group, aryl group, cycloalkyl group, or R 1 and R 2 are bound to form an alicyclic ring, R 3 is a hydrogen atom or an alkyl group, R 4 is a branched alkyl group or an alkyl group that does or does not form a ring by itself, or an unsubstituted or substituted aryl group, or an unsubstituted or substituted heterocyclic group, Ar is an unsubstituted or substituted cyclopentadienyl group that is bound to M via a π bond, or an unsubstituted or substituted benzene, X is a hydride group or an anionic group, M is ruthenium, rhodium or iridium, L is a solvent molecule or a water molecule, l is 1 or 2, m is an integer from 0 to 2, n is 0 or 1, and when n is 0, X does not exist, and * represents asymmetric carbon, wherein R 4 is not a camphor group, a camphor derivative group, an isopropyl group or a phenyl group whenever R 1 and R 2 are both a phenyl group.

  本发明提供一种有机金属化合物、配体、不对称催化剂以及利用该不对称催化剂制备光学活性醇的方法。本发明的有机金属化合物由以下通用式（1）表示： 在通用式（1）中，R1和R2是相互相同或相互不同的未取代或取代的烷基基团、芳基团、环烷基团，或R1和R2结合形成脂环，R3是氢原子或烷基基团，R4是支链烷基基团或自身形成环或不形成环的烷基基团，或未取代或取代的芳基团，或未取代或取代的杂环基团，Ar是通过π键与M结合的未取代或取代的环戊二烯基团，或未取代或取代的苯，X是氢化物基团或阴离子基团，M是钌、铑或铱，L是溶剂分子或水分子，l为1或2，m为0到2的整数，n为0或1，当n为0时，X不存在，*代表不对称碳，其中当R1和R2均为苯基团时，R4不是藿香基团、藿香衍生基团、异丙基团或苯基团。
• Efficient synthesis of 5-heteroatom-containing -pyrazoles
  申请人：——

  公开号：US20030139407A1

  公开（公告）日：2003-07-24

  An efficient synthesis of sulfonyl pyrazoles of formula I: 1 wherein the ring of the formula (R 5 )—A—(SO m R 4 ), m, R 1 through R 9 are as defined in the specification, comprising reacting a compound of formula II: 2 wherein the ring of the formula (R 5 )—A—(SO m 4 ), m R 1 through R 9 are as defined above and wherein R 10 is halo, (C 1 -C 6 )alkyl-SO 3 —, (C 6 -C 10 )aryl-SO 3 —, (C 1 -C 6 )alkyl-SO 2 —, or (C 6 -C 10 )aryl-SO 2 —; wherein each of said (C 1 -C 6 )alkyl component of said (C 1 -C 6 )alkyl-SO 3 — and (C 1 -C 6 )alkyl-SO 2 — radicals may optionally be substituted on any carbon atom by one to six fluoro substituents per (C 1 -C 6 )alkyl component; with a compound of formula R 3 —H, wherein R 3 is as defined above, in the presence of a fluoride containing salt and in the presence of a solvent.

  一种有效的合成公式I：1的磺酰吡唑，其中公式的环（R5）-A-（SOmR4），m，R1到R9如规范中所定义，包括在氟化物盐和溶剂的存在下，将公式II的化合物反应：2其中公式的环（R5）-A-（SOm4），m，R1到R9如上所定义，其中R10是卤素，（C1-C6）烷基-SO3-，（C6-C10）芳基-SO3-，（C1-C6）烷基-SO2-或（C6-C10）芳基-SO2-；其中每个（C1-C6）烷基-SO3-和（C1-C6）烷基-SO2-基团的（C1-C6）烷基组分可以选择地被每个碳原子取代一个到六个氟代基。其中R3为上述定义的化合物R3-H进行反应。
• 5-Heteroatom-substituted pyrazoles
  申请人：——

  公开号：US20030134858A1

  公开（公告）日：2003-07-17

  The present invention relates to 5-heteroatom-substituted pyrazoles of the formula I: 1 wherein the ring of the formula (R 5 )-A-(SO m R 4 ), m, B, R 1 through R 5 are as defined in the specification, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the invention are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as arthritis, colon cancer, and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.

  本发明涉及公式I的5-杂原子取代吡唑，其中公式(R5)-A-(SOmR4)，m，B，R1到R5的环在说明书中定义，以及包含它们的制药组合物和它们的药用。本发明的化合物在哺乳动物，特别是人类、狗、猫和家畜动物中用于治疗或缓解炎症和其他与炎症相关的疾病，如关节炎、结肠癌和阿尔茨海默病等方面有用。
• Hydrazinyl and nitrogen oxide pyrazoles
  申请人：Pfizer Inc.

  公开号：US20030134850A1

  公开（公告）日：2003-07-17

  The present invention relates to hydrazinyl and nitrogen oxide pyrazoles of the formula I: 1 wherein the ring of the formula (R 5 )-A-(SO m R 4 ), m, X, R 1 through R 5 are as defined in the specification, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the invention are useful in the treatment or alleviation of inflammation and other inflammation associated disorders, such as arthritis, colon cancer and Alzheimer's disease in mammals, preferably humans, dogs, cats and livestock animals.

  本发明涉及式I的肼基和氮氧化物吡唑：1其中，式（R5）-A-（SOmR4），m，X，R1至R5的环如规范中所定义，以及包含它们的制药组合物和它们的医药用途。本发明的化合物在哺乳动物中，尤其是人类、狗、猫和家畜动物中，用于治疗或缓解炎症和其他与炎症相关的疾病，如关节炎、结肠癌和阿尔茨海默病。